The USFDA recently approved an oral, fixed-dose combination therapy of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis (ALS) . The drug was found to significantly slow down the progression of physical symptoms of ALS in a randomized, placebo-controlled clinical trial. Recommended dosage One packet of medication containing 3 gm sodium phenylbutyrate and 1 gm taurursodiol, mixed in 8 ounces of water Taken once daily for the first three weeks, following which the dose is increased to two packets a day The medication should be taken before meals.
Clinical trial data Patients in the treatment group experienced a slower rate of decline in motor symptoms compared to the placebo group. Adverse events Diarrhea Abdominal pain Upper respiratory tract infection Dizziness Fatigue Precautions The drug can worsen gastrointestinal symptoms in…
